去甲氧柔红霉素治疗急性白血病的临床疗效观察  

EFFICACY OF IDARUBICIN IN THE TREATMENT OF ACUTE LEUKEMIA: A CLINICAL OBSERVATION

作　　者：曾晓颖[1] 陈瑜[1] 周励[1] 张芬琴[1] 李秀松[1] 沈志祥[1] 

机构地区：[1]上海第二医科大学附属瑞金医院血液科,上海200025

出　　处：《中国癌症杂志》1998年第1期72-74,共3页China Oncology

摘　　要：目的 观察和比较去甲氧柔红霉素治疗急性的初治、复发以及难治性白血病的临床疗效.方法34例急性白血病应用去甲氧柔红霉素辅以其它药物的联合化疗,分为初治组、复发组和难治组三组进行疗效观察比较.结果总有效率达70.6%,初治组与复发组疗效比较有显著性差异(P<0.05),初治组与难治组比较疗效有显著性差异(P<0.01).结论 去甲氧柔红霉素是一种新型、有效的治疗急性白血病的药物.PURPOSEObservation of clinical efficacy of idarubicin in the treatment of patients with both newly-diagnosed and relapsed/refractory acute leukemia. METHODS 34 patients of acute leukemia enrolled in this study are classified into 3 groups: newly-diagnosed, relapsed and refractory group. All patients are treated with combination chemotherapy composed of idarubicin and other agents. RESULTS The response rate for all patients is 70. 6% while the result in newly-diagnosed group is superior to both relapsed and refractory group (P<0. 05 and P< 0. 01). CONCLUSION Idarubicin is a very effective agent in the treatment of acute leukemia.

关 键 词：急性 白血病 去甲氧柔红霉素 药物疗法 

分 类 号：R733.710.5[医药卫生—肿瘤] R979.1[医药卫生—临床医学]